A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.

Trial Profile

A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs PL MLP (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Lipomedix Pharmaceuticals
  • Most Recent Events

    • 04 Jul 2017 Number of arms changed from 10 to 12,hence patient number has also changd from 48 to 90.
    • 04 Jul 2017 Planned number of patients changed from 48 to 90.
    • 04 Jul 2017 Status changed from completed to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top